Neurocrine Biosciences Inc at Barclays Global Healthcare Conference Transcript
Good morning, and welcome to Day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays.
I am pleased to welcome Neurocrine Biosciences, just recently celebrating your 30th Anniversary. Joining us on stage, Kevin Gorman, CEO; and CFO, Matt Abernethy.
Kevin is going to make some opening comments.
I will make -- I'll keep them brief. And I want to thank Barclays, I want to thank you, Carter, for the invitation here. We always love coming to this conference in Miami. I would also say that we are going to be making forward-looking statements. So I would -- you to our more recent SEC filings.
So as Carter said, Neurocrine just recently celebrated its 30th Anniversary. We are a (inaudible) world neuroscience company. What does neuroscience mean to us? That means neurology, neuropsychiatry and neuroendocrinology and hopefully, someday,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
